Ongoing Clinical Trials for Viral Respiratory Tract Infection
Currently, there is 1 ongoing clinical trial investigating the management of viral respiratory tract infections in hospitalized adults. This study focuses on evaluating the safety of discontinuing antibiotic treatment in patients who test positive for specific respiratory viruses. The trial is being conducted in Norway and examines whether stopping antibiotics is as safe and effective as continuing them in patients with confirmed viral infections.
Clinical trial locations
Study on Stopping Antibiotics in Adults with Viral Respiratory Infections Using Tetracyclines and Other Antibiotics
This clinical trial examines whether it is safe to stop antibiotic treatment in adults who have viral respiratory infections. The study is designed for patients who have already started taking antibiotics but later test positive for viruses such as influenza, parainfluenza, respiratory syncytial virus (RSV), or human metapneumovirus (hMPV).
Main inclusion criteria:
- Adults aged 18 years or older who are hospitalized
- Patients with moderately severe disease, measured by a CRB65 score of 2 or less (this score evaluates confusion, breathing rate, blood pressure, and age)
- Positive nasopharyngeal swab test confirming infection with influenza virus, parainfluenza virus, RSV, or hMPV
- Currently receiving antibiotic therapy started in the emergency department
- Able to provide signed informed consent
Main exclusion criteria:
- Patients without a positive test for respiratory viruses in their airway sample
- Patients outside the specified age range
- Patients belonging to vulnerable populations who might need special protection or care
Focus and goal of the trial: The main purpose of this study is to determine whether stopping antibiotics is as safe and effective as continuing them in patients with confirmed viral respiratory infections. Since viral infections do not respond to antibiotics, continuing these medications may be unnecessary and could contribute to antibiotic resistance. The trial will compare patients who stop their antibiotic treatment with those who continue it, monitoring their recovery and health outcomes over time.
The study evaluates several important outcomes, including patient recovery within 120 hours after joining the study, survival rates, length of hospital stay, and any need for additional antibiotic treatment. Researchers will also track hospital readmissions and new antibiotic prescriptions up to 30 days after discharge.
Investigational approach: The study examines antibiotic therapy itself, specifically evaluating various classes of antibiotics including tetracyclines, beta-lactam antibacterials (such as amoxicillin), fluoroquinolones, lincosamides, aminoglycosides, and trimethoprim derivatives. Participants are randomly assigned to either continue or discontinue their antibiotic treatment, allowing researchers to compare the safety and effectiveness of both approaches.
Summary
This trial addresses an important clinical question about antibiotic use in viral respiratory infections. With only one trial currently ongoing in this area, the study being conducted in Norway represents a focused effort to improve antibiotic stewardship. The research specifically targets hospitalized adults with confirmed viral infections who have already begun antibiotic treatment, a common scenario in emergency departments where initial treatment decisions must be made before viral test results are available.
The study’s design reflects growing concerns about unnecessary antibiotic use and antimicrobial resistance. By evaluating whether it is safe to stop antibiotics once a viral infection is confirmed, the trial may provide valuable evidence to guide clinical practice and reduce inappropriate antibiotic use in patients with viral respiratory infections.
